MX355088B - Inhibidores de tienopirimidina de proteina cinasa c atipica. - Google Patents

Inhibidores de tienopirimidina de proteina cinasa c atipica.

Info

Publication number
MX355088B
MX355088B MX2014006233A MX2014006233A MX355088B MX 355088 B MX355088 B MX 355088B MX 2014006233 A MX2014006233 A MX 2014006233A MX 2014006233 A MX2014006233 A MX 2014006233A MX 355088 B MX355088 B MX 355088B
Authority
MX
Mexico
Prior art keywords
protein kinase
atypical protein
thienopyrimidine
inhibitors
thienopyrimidine inhibitors
Prior art date
Application number
MX2014006233A
Other languages
English (en)
Other versions
MX2014006233A (es
Inventor
D Dorsey Bruce
S Learn Keith
L Morris Emma
R Ott Gregory
R Roffey Jonathan
N Soudy Christellen
C Wagner Jason
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MX2014006233A publication Critical patent/MX2014006233A/es
Publication of MX355088B publication Critical patent/MX355088B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Abstract

La presente invención proporciona un compuesto de la fórmula (I) (ver Fórmula) o una sal del mismo, en donde R1, R2, R3, R4, R5, R6, A, G, M, Q y X son como se define en la presente. Un compuesto de la fórmula (I) y sus sales tiene una actividad inhibidora de PKCa y pueden utilizarse para tratar trastornos proliferativos.
MX2014006233A 2011-11-23 2012-11-19 Inhibidores de tienopirimidina de proteina cinasa c atipica. MX355088B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563310P 2011-11-23 2011-11-23
PCT/US2012/065831 WO2013078126A1 (en) 2011-11-23 2012-11-19 Thienopyrimidine inhibitors of atypical protein kinase c

Publications (2)

Publication Number Publication Date
MX2014006233A MX2014006233A (es) 2014-10-17
MX355088B true MX355088B (es) 2018-04-04

Family

ID=47295200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006233A MX355088B (es) 2011-11-23 2012-11-19 Inhibidores de tienopirimidina de proteina cinasa c atipica.

Country Status (12)

Country Link
US (3) US9604994B2 (es)
EP (2) EP2782917B1 (es)
JP (1) JP6206926B2 (es)
CN (1) CN104053661B (es)
AU (2) AU2012340869B2 (es)
CA (1) CA2855446C (es)
ES (1) ES2575143T3 (es)
HK (1) HK1202529A1 (es)
IL (1) IL232559B (es)
IN (1) IN2014CN04558A (es)
MX (1) MX355088B (es)
WO (1) WO2013078126A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097013A1 (en) 2011-01-10 2012-07-19 Nimbus Iris, Inc. Irak inhibitors and uses thereof
TW201728592A (zh) * 2012-01-10 2017-08-16 林伯士艾瑞斯公司 Ｉｒａｋ抑制劑及其用途
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
JP2015528801A (ja) 2012-07-11 2015-10-01 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
BR112015014034A2 (pt) 2013-01-10 2017-07-11 Nimbus Iris Inc inibidores de irak e usos dos mesmos
KR20160092991A (ko) 2013-09-27 2016-08-05 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
TWI675836B (zh) 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑
SG11201804901WA (en) * 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
KR20180075228A (ko) * 2016-12-26 2018-07-04 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
WO2019119206A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN108658999B (zh) * 2018-04-24 2021-02-05 温州大学 2-苯基杂环并[2,3-d]嘧啶-4(3H)-酮类化合物的合成方法
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
AU2019385480A1 (en) * 2018-11-20 2021-07-15 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
EP3725788A1 (en) * 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
CN116410205A (zh) * 2021-12-29 2023-07-11 上海皓元生物医药科技有限公司 一种3-取代-9-甲基-噻吩并***并噁嗪类化合物的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
EA200200424A1 (ru) 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
AU2001290311A1 (en) 2000-09-29 2002-04-08 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
AU2002364536B2 (en) 2001-12-07 2008-10-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
TW200410975A (en) 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
MXPA05013549A (es) 2003-06-11 2006-04-05 Xention Discovery Ltd Derivados de tienopirimidina como inhibidores del canal de potasio.
US20050165029A1 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP1758453B1 (en) 2004-06-15 2014-07-16 Merck Sharp & Dohme Corp. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
WO2006010568A2 (de) 2004-07-23 2006-02-02 Curacyte Discovery Gmbh Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung
DE102005013621A1 (de) 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
KR101422301B1 (ko) 2006-04-26 2014-07-30 에프. 호프만-라 로슈 아게 약학적 화합물
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
ZA200904531B (en) * 2006-12-07 2010-09-29 Hoffmann La Roche Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2009144584A1 (en) 2008-05-30 2009-12-03 Mitologics Anti-ligands molecules and biological applications
JP5452617B2 (ja) * 2009-01-08 2014-03-26 キュリス，インコーポレイテッド 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター
BR112012010186B8 (pt) 2009-10-29 2021-05-25 Palau Pharma Sa derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療

Also Published As

Publication number Publication date
AU2012340869A1 (en) 2014-06-19
ES2575143T3 (es) 2016-06-24
US20140323435A1 (en) 2014-10-30
AU2012340869B2 (en) 2017-03-02
AU2017203725B2 (en) 2019-02-28
IL232559A0 (en) 2014-06-30
NZ625447A (en) 2015-09-25
CA2855446A1 (en) 2013-05-30
HK1202529A1 (zh) 2015-10-02
EP3048106B1 (en) 2019-11-06
MX2014006233A (es) 2014-10-17
US10183950B2 (en) 2019-01-22
US20170158706A1 (en) 2017-06-08
EP2782917A1 (en) 2014-10-01
AU2017203725A1 (en) 2017-06-22
JP2014533728A (ja) 2014-12-15
CN104053661A (zh) 2014-09-17
EP3048106A1 (en) 2016-07-27
US9604994B2 (en) 2017-03-28
EP2782917B1 (en) 2016-03-02
US20190106433A1 (en) 2019-04-11
US10954251B2 (en) 2021-03-23
CA2855446C (en) 2021-04-20
CN104053661B (zh) 2018-06-19
JP6206926B2 (ja) 2017-10-04
WO2013078126A1 (en) 2013-05-30
IN2014CN04558A (es) 2015-09-18
IL232559B (en) 2018-04-30

Similar Documents

Publication Publication Date Title
MX355088B (es) Inhibidores de tienopirimidina de proteina cinasa c atipica.
PH12015500689A1 (en) Azaquinazoline inhibitors of atypical protein kinase c
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
UA111382C2 (uk) Інгібітори протеїнкінази
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
MY172924A (en) Neprilysin inhibitors
MY162167A (en) Substituted acetyl-coa carboxylase inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201492210A1 (ru) Соединения, ингибирующие активность катехол-o-метилтрансферазы
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
PH12014501979A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1
MX2015009678A (es) Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CANCER RESEARCH TECHNOLOGY LIMITED

FG Grant or registration